Dr. Patrick M. Grierson, MD

Dr. Grierson practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Grierson's NPI, 1720492192, was assigned on June 13, 2014. Dr. Grierson graduated from Ohio State University College of Medicine in 2014. Dr. Grierson holds Missouri license 2017020379.

Dr. Grierson's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Grierson also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Grierson's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Grierson is also affiliated with Christian Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Grierson to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Grierson practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Grierson's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Grierson is licensed in Missouri.

CMS data shows 6,256 Medicare services from Dr. Grierson across 24 procedure codes in 2024, for 250 Medicare patients. Medicare paid $56,556 for them.

CMS counts 250 Medicare patients who saw Dr. Grierson in 2024. The largest group is 65 to 74, with 122 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Grierson's median patient age at 71, with 45% women.

In 2024, Dr. Grierson wrote 1,386 Medicare Part D claims for 161 patients. 86% of them were for generic drugs. CMS names the drug for 1,158 of them, across 28 drugs with 11 or more claims each, at $194,367 in total drug cost. In 2023, CMS named 898 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Grierson for performance year 2024, reported as part of a group. Dr. Grierson accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 26 papers to Dr. Grierson, published from 2011 to 2024. 2021 was the busiest year, with 4. The most frequent topics are Pancreatic Neoplasms, Cell Line, Tumor and Carcinoma, Pancreatic Ductal. Dr. Grierson has published most often in Clin Cancer Res. Dr. Grierson's most frequent co-authors are Katrina Sophia Pedersen, MD, Manik A. Amin, MD and Rama Suresh, MD.

Dmand AI links Dr. Grierson to 6 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Pancreatic Neoplasms, Pancreatic Diseases and Rectal Neoplasms. Washington University School of Medicine sponsors the most, 5.

CMS Open Payments shows 18 general payments to Dr. Grierson from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. AstraZeneca Pharmaceuticals LP paid the most, $2,200.

Dr. Grierson graduated from Ohio State University College of Medicine in 2014.